Resilinc Special Report

Life Sciences Supply Chains in 2025: Addressing Disruptions and Strengthening Resilience

Life sciences supply chains are rapidly changing due to new regulations, geopolitical tensions, and supply chain disruptions. Stricter compliance rules, increased government oversight, and policies like the U.S. Biosecure Act are reshaping global sourcing strategies. Companies are reducing reliance on China through nearshoring, supplier diversification, and domestic production to enhance stability.
To navigate these shifts, businesses are focusing on strategic planning in supply chains, leveraging AI-driven compliance tools, blockchain tracking, and predictive analytics to mitigate risk and improve visibility. This report explores key life sciences supply chain trends and strategies to help organizations strengthen supply chains, enhance resilience, and adapt to evolving regulatory and economic pressures.
Key Insights:
  • FDA and MDR compliance costs have increased by 20% YoY, pushing companies to automate regulatory tracking and invest in supply chain transparency
  • Lithium and rare earth element demand is projected to outpace supply by 30% by 2027, accelerating domestic mining and alternative material research
  • The U.S. Biosecure Act has led to a 15% reduction in biotech imports from China, forcing companies to shift sourcing to India, Eastern Europe, and Latin America